Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.61 |
| ▸ | DRD2 | P14416 | 13/20 | 0.61 |
| ▸ | HTR2A | P28223 | 6/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 5/20 | 0.53 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14372241 | 0.86 | DRD2 (0.62) | DRD3DRD2 | |
| SCHEMBL5468391 | 0.85 | DRD2 (0.56) | DRD3DRD2LMNA | |
| SCHEMBL5466255 | 0.83 | GFER (0.63) | LMNA | |
| SCHEMBL5466569 | 0.82 | MAPT (0.52) | DRD3DRD2HTR1A | |
| SCHEMBL5468384 | 0.79 | DRD2 (0.62) | DRD3DRD2LMNA | |
| SCHEMBL4527921 | 0.79 | DRD3 (0.63) | DRD3DRD2HTR2AHRH1KCNH2 | |
| SCHEMBL10401903 | 0.78 | DRD2 (0.72) | DRD3DRD2HTR1A | |
| SCHEMBL10401593 | 0.78 | DRD2 (0.72) | DRD3DRD2HTR1A | |
| SCHEMBL14372243 | 0.78 | DRD3 (0.57) | DRD3DRD2 | |
| SCHEMBL314986 | 0.78 | DRD2 (0.83) | DRD3DRD2HTR2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | DRD3 78/4885DRD2 34/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.